抗登革病毒化学药物研究进展

张高红, 郑永唐

中国药学杂志 ›› 2017, Vol. 52 ›› Issue (10) : 809-813.

PDF(1124 KB)
PDF(1124 KB)
中国药学杂志 ›› 2017, Vol. 52 ›› Issue (10) : 809-813. DOI: 10.11669/cpj.2017.10.001
综述

抗登革病毒化学药物研究进展

  • 张高红, 郑永唐
作者信息 +

Research Progress of Chemical Drugs Against Dengue Virus

  • ZHANG Gao-hong, ZHENG Yong-tang*
Author information +
文章历史 +

摘要

登革热是由埃及伊蚊和白纹伊蚊传播的一种重要虫媒病毒引起的疾病。登革病毒感染能够引起登革热、登革出血热和登革休克综合征等多种症状。迄今为止尚无抗登革病毒药物上市。研发中的药物按照作用机制可分为抗登革病毒的复制周期抑制剂和对抗宿主的宿主因子抑制剂两大类。依据作用靶点不同,前者又进一步分为登革病毒进入抑制剂、衣壳蛋白抑制剂、NS3蛋白抑制剂、NS5蛋白抑制剂、NS4B蛋白抑制剂;后者分为细胞受体抑制剂、脂类合成及代谢途径抑制剂、葡萄糖苷酶抑制剂。目前抗登革病毒的药物研发仍面临巨大挑战,研发作用于登革病毒4种血清型的有效药物具有广阔的应用前景,必将为登革热的防治带来新希望。

Abstract

Dengue fever is one of the most important vector-borne human diseases caused by mosquito vector Aedes aegypti and Aedes albopictus. Dengue virus can cause dengue fever, dengue hemorrhagic fever and dengue shock syndrome. There are no approved drugs for the treatment of dengue disease so far. According to the mechanism of anti-dengue virus(anti-DENV) action, drugs under development for dengue disease can be divided into two categories:viral replication inhibitors and anti-cell factor pathway inhibitors. The former is further divided into DENV entry inhibitors, capsid protein inhibitors, NS3 protein inhibitors, NS5 protein inhibitors, and NS4B protein inhibitors; the latter is further divided into cell receptor inhibitors, lipid synthesis and metabolism inhibitors, and glucosidase inhibitors. The R&D of anti-DENV drugs is facing enormous challenges. Development of effective drugs which can be used for the treatment of four serotypes of dengue has a broad application prospect, and it will bring new hopes for dengue fever prevention and therapy.

关键词

登革热 / 登革热病毒 / 登革出血热 / 登革休克综合征 / 抗登革病毒药物

Key words

dengue fever / dengue virus / dengue hemorrhagic fever / dengue shock syndrome / anti-dengue virus

引用本文

导出引用
张高红, 郑永唐. 抗登革病毒化学药物研究进展[J]. 中国药学杂志, 2017, 52(10): 809-813 https://doi.org/10.11669/cpj.2017.10.001
ZHANG Gao-hong, ZHENG Yong-tang. Research Progress of Chemical Drugs Against Dengue Virus[J]. Chinese Pharmaceutical Journal, 2017, 52(10): 809-813 https://doi.org/10.11669/cpj.2017.10.001
中图分类号: R97   

参考文献

[1] MURRAYN E,QUAM M B,WILDER-SMITH A. Epidemiology of dengue:past, present and future prospects [J]. Clin Epidemiol, 2013, 5:299-309. doi:10.2147/CLEP.S34440.
[2] XIONG Y Q, CHEN Q. Epidemiology of dengue fever in China since 1978[J]. J South Med Univ (南方医科大学学报), 2014, 34(12):1822-1825.
[3] LANTERI M C, BUSCH M P. Dengue in the context of “safe blood” and global epidemiology:to screen or not to screen [J]. Transfusion, 2012, 52(8):1634-1639.
[4] WALKER T, JOHNSON P H, MOREIRA L A, et al. The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations [J]. Nature, 2011, 476(7361):450-453.
[5] MULLER D A, YOUNG P R. The flavivirus NS1 protein:molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker [J]. Antiviral Res, 2013, 98(2):192-208.
[6] LIM S P, WANG Q Y, NOBLE C G, et al. Ten years of dengue drug discovery:progress and prospects [J]. Antiviral Res, 2013, 100(2):500-519.
[7] WHITEHORN J, YACOUB S, ANDERS K L, et al. Dengue therapeutics, chemoprophylaxis, and allied tools:state of the art and future directions [J]. PLoS Negl Trop Dis, 2014, 8(8):e3025.
[8] MODIS Y, OGATA S, CLEMENTS D, et al. A ligand-binding pocket in the dengue virus envelope glycoprotein [J]. Proc Natl Acad Sci USA, 2003, 100(12):6986-6991.
[9] TAMBUNAN U S, ZAHROH H, PARIKESIT A A, et al. Screening analogs of β-OG pocket Binder as fusion inhibitor of dengue virus 2 [J]. Drug Target Insights, 2015, 9:33-49. doi:10.4137/DTI. S21566.
[10] SCHMIDT A G, YANG P L, HARRISON S C. Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate [J]. PLoS Pathog, 2010, 6(4):e1000851.
[11] NICHOLSON C O, COSTIN J M, ROWE D K, et al. Viral entry inhibitors block dengue antibody-dependent enhancement in vitro [J]. Antiviral Res, 2011, 89(1):71-74.
[12] BYRD C M, DAI D, GROSENBACH D W, et al. A novel inhibitor of dengue virus replication that targets the capsid protein [J]. Antimicrob Agents Chemother, 2013, 57(1):15-25.
[13] SCATURRO P, TRIST I M, PAUL D, et al. Characterization of the mode of action of a potent dengue virus capsid inhibitor [J]. J Virol, 2014, 88(19):11540-11555.
[14] YANG C C, HU H S, WU R H, et al. A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease [J]. Antimicrob Agents Chemother, 2014, 58(1):110-119.
[15] YIN Z, PATEL S J, WANG W L, et al. Peptide inhibitors of dengue virus NS3 protease. Part 2:SAR study of tetrapeptide aldehyde inhibitors [J]. Bioorg Med Chem Lett, 2006, 16(1):40-43.
[16] SMITH T M, LIM S P, YUE K, et al. Identifying initiation and elongation inhibitors of dengue virus RNA polymerase in a high-throughput lead-finding campaign [J]. J Biomol Screen, 2015, 20(1):153-163.
[17] FRASER J E, WATANABE S, WANG C, et al. A nuclear transport inhibitor that modulates the unfolded protein response and provides in vivo protection against lethal dengue virus infection [J]. J Infect Dis, 2014, 210(11):1780-1791.
[18] TAY M Y, FRASER J E, CHAN W K, et al. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ive rmectin [J]. Antiviral Res, 2013, 99(3):301-306.
[19] FRASER J E, RAWLINSON S M, WANG C, et al. Investigating dengue virus nonstructural protein 5 (NS5) nuclear import [J]. Methods Mol Biol, 2014, 1138:301-328. doi:10.1007/978-1-4939-0348-119.
[20] VAN CLEEF K W, OVERHEUL G J, THOMASSEN M C, et al. Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication [J]. Antiviral Res, 2013, 99(2):165-171.
[21] KRISHNAN M N, GARCIA-BLANCO M A. Targeting host factors to treat west nile and dengue viral infections [J]. Viruses, 2014, 6(2):683-708.
[22] KWON Y J, HEO J, WONG H E, et al. Kinome siRNA screen identifies novel cell-type specific dengue host target genes [J]. Antiviral Res, 2014, 110:20-30. doi:10.1016/j.antiviral. 2014.07.006.
[23] MARQUES R E, GUABIRABA R, DEL SARTO J L, et al. Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development [J]. Immunology, 2015, 145(4):583-596.
[24] ROTHWELL C, LEBRETON A, YOUNG N G C, et al. Cholesterol biosynthesis modulation regulates dengue viral replication [J]. Virology, 2009, 389(1-2):8-19.
[25] MARTINEZ-GUTIERREZ M, CASTELLANOS J E, GALLEGO-GOMEZ J C. Statins reduce dengue virus production via decreased virion assembly [J]. Intervirology, 2011, 54(4):202-216.
[26] POH M K, SHUI G, XIE X, et al. U18666A, an intra-cellular cholesterol transport inhibitor, inhibits dengue virus entry and replication [J]. Antiviral Res, 2012, 93(1):191-198.
[27] VILLAREAL V A, RODGERS M A, COSTELLO D A, et al. Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses [J]. Antiviral Res, 2015, 124:110-121. doi:10.1016/j.antiviral. 2015.10.013.
[28] WHITBY K, PIERSON T C, GEISS B, et al. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo [J]. J Virol, 2005, 79(14):8698-8706.
[29] MILLER J L, LACHICA R, SAYCE A C, et al. Liposome-mediated delivery of iminosugars enhances efficacy against dengue virus in vivo [J]. Antimicrob Agents Chemother, 2012, 56(12):6379-6386.

基金

国家自然科学基金资助项目(81273251,81172876)
PDF(1124 KB)

Accesses

Citation

Detail

段落导航
相关文章

/